of 0.48, 0.46, 0.31, 0.27, 0.32, and 0.57 cases per ICU bed over 4 weeks in Europe, North America, South America, Asia, Africa, and Oceania, respectively. [2] Compared to non-ARDS patients, the mortality of ARDS patients is significantly higher (29.0% vs. 12.0%). More importantly, mortality increases to over 40.0% when patients progress to severe ARDS. Therefore, it is urgent for clinicians to achieve early recognition and diagnosis.
thE BErlIn dEfInItIon of acutE rEsPIratory dIstrEss syndromE Is commonly usEd But not PErfEct
It has been 50 years since Ashbaugh et al. [7] first termed "ARDS" as a syndrome characterized by "acute onset of tachypnea, hypoxemia, and loss of compliance after a variety of stimuli" in 1967. Since then, it has been a long path to define ARDS. There is much controversy in the definition of ARDS from the "Murray Lung Injury Score" to "the American-European Consensus Conference (AECC) definition" to "the Berlin definition."
Compared with the AECC definition, the Berlin definition specifies the following: acute onset within 1 week; the source of lung edema, considering the coexistence of cardiogenic pulmonary edema and original disease factors; characteristics of the bilateral lung infiltrates on the chest X-ray or CT scan; hypoxemia evaluated with a positive end-expiratory pressure (PEEP) level ≥5 cmH 2 O (1 cmH 2 O = 0.098 kPa); and lung injury divided into three grades of severity according to the partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO 2 /FiO 2 ) ratio. The predictive validity for mortality was significantly improved by the Berlin definition of ARDS. [8] However, the definition is still controversial. First, the current clinical tools cannot identify the pathological change of ARDS; second, the lack of a specific biomarker might influence diagnostic specificity; and third, the stratification of ARDS patients as proposed by the Berlin criteria is less useful for assessing the severity of lung injury and depends on the patient's therapeutic response. [9] More than 60.0% of patients with severe ARDS according to the Berlin criteria were reclassified as moderate, mild, or non-ARDS after 24 h of usual care, and hospital mortality changed significantly. [10] Finally, although the Berlin definition has higher predictive validity for mortality than the AECC definition, the specificity of the Berlin definition for ARDS was relatively poor when using diffuse alveolar damage as the reference standard, and the predictive validity of the Lung Injury Score for mortality was similar to the Berlin definition stages of severity with an area under the curve of 0.58 compared to 0.60. [11, 12] acutE rEsPIratory dIstrEss syndromE Is stIll undEr rEcognItIon ARDS could worsen patients' prognosis, and the mortality between ARDS and non-ARDS is significantly different. [13] In the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (Lung SAFE) study, 60.2% of all patients with ARDS were clinician recognized, and the clinician's diagnosis of ARDS ranged from 51.3% (95% CI, 47.5-55.0%) for mild ARDS to 78.5% (95% CI, 74.8-81.8%) for severe ARDS. [14] Several factors influence the early diagnosis of ARDS. Higher nurse-to-patient ratios, higher physician-to-patient ratios, younger patient age, lower PaO 2 /FiO 2 ratio, and the presence of pneumonia or pancreatitis were factors independently associated with higher probability of clinician recognition.
There are still some factors associated with a lower probability of early recognition of ARDS. Absence of a risk factor and presence of concomitant cardiac failure were associated with reduced likelihood of clinician recognition of ARDS. [2, 15] tIdal volumE should BE IndIvIdualIzEd Although low tidal volume (VT) has been proved to decrease ARDS mortality, 6 ml/kg predicted body weight (PBW) VT is not suitable for all ARDS patients. Terragni et al. [16] found that VT of 6 ml/kg PBW and plateau pressure of 30 cmH 2 O might not be sufficient to protect two-third of ARDS patients from dynamic hyperinflation. In fact, nonphysiological lung strain and stress could induce ventilator-induced lung injury (VILI), either globally or locally. It has been found that dynamic strain is still higher in many ARDS patients ventilated with even 6 ml/kg PBW. [17] To minimize VILI, it is more reasonable to normalize VT to individual lung size. A former study showed that pulmonary compliance is associated with end-expiratory lung volume (EELV). [18, 19] To address this issue, airway driving pressure (quotient of VT/Crs) is proposed to substitute for lung dynamic strain. [20] Amato et al. [21] used multilevel mediation analysis to analyze individual data from 3562 patients with ARDS enrolled in nine randomized trials; they showed that decreases in driving pressure due to changes in ventilator settings were strongly associated with increased survival. Further study is needed to demonstrate whether driving pressure could be a goal of the individualized setting of VT in itself.
Airway driving pressure could be used as a safety limit during VT titration at the bedside. It has been demonstrated that driving pressure during mechanical ventilation is directly related to stress forces in the lung. Optimal cutoff values for airway driving pressure of 15.0 cmH 2 O and 16.6 cmH 2 O were considered as stress equal to or greater than 24 cmH 2 O and 26 cmH 2 O, respectively. [22] In the clinical scenario, airway driving pressure is affected by chest wall compliance and spontaneous breathing. Inhibition of spontaneous breathing might be necessary during the measurement of airway driving pressure. However, routine measurement of transpulmonary driving pressure is not suggested since linear regression between transpulmonary and airway driving pressure has been found in 150 ARDS patients. [22] In severe ARDS patients, a lower VT strategy for lung protection might be followed by refractory hypoxemia or hypercapnia. In this scenario, extracorporeal membrane oxygenation (ECMO) or extracorporeal CO 2 elimination should be used as the first-line rescue treatment to improve oxygenation or CO 2 elimination. Positive results of the CESAR trial have led to an exponential use of these technologies in the recent years. [23] The initial time of ECMO in patients with ARDS remains controversial, but the early use of ECMO could protect lungs from VILI. [24] Indeed, ECMO is one of the most effective methods for lung protection, allowing very low VT leading to "lung rest."
PathoPhysIologIcal charactErIstIcs guIdIng lung rEcruItmEnt and PosItIvE End-ExPIratory PrEssurE tItratIon
Lung recruitment maneuvers (RMs) will be beneficial when properly applied to appropriately selected patients with high lung recruitability. A meta-analysis of six clinical trials has suggested RMs with higher PEEP-reduced mortality in patients with moderate and severe ARDS, but this finding has not been confirmed in randomized clinical trials. [25] [26] [27] Recently, a large randomized clinical trial compared patients treated with the RMs and titrated PEEP (n = 501) with those managed with conventional PEEP (n = 509) in moderate-to-severe ARDS (PaO 2 /FiO 2 ≤200). [28] The result showed that a strategy with lung recruitment and titrated PEEP compared with the control group increased 28-day all-cause mortality, and RMs were associated with pulmonary complication in patients with moderate-to-severe ARDS. There are several reasons for the surprising results. First, RMs are suitable for high recruitability patients, but this study recruited more pneumonia patients, which had been demonstrated to have low lung recruitability; second, the pressure in the RM group is higher than that in former studies, which could increase the incidence of pneumothorax and barotrauma, complications of which are disastrous for severe ARDS; third, there are more septic shock patients in this study, and RMs could lead to hemodynamic variation, which might be the reason why the mortality is high in the RM group; fourth, the relatively high recruitment pressure will deteriorate hemodynamic stability and lead to more fluid administration; and fifth, RMs might be more beneficial in the early phase of ARDS, but the RMs were used for 7 days in this study. RMs remind clinician, not only severity of ARDS, but lung recruitability, phase of ARDS, recruitment pressure limitation, and hemodynamic stability should also be considered. [29] Prone position ventilation is another method of lung recruitment, especially for ARDS patients with low lung recruitability. Due to its beneficial effects in improving ventilation-perfusion matching, increasing EELV, and decreasing VILI by a more uniform distribution of VT through lung recruitment and alterations in chest wall mechanics, prone position ventilation should be considered in the early phase of ARDS in patients with PaO 2 /FiO 2 <150 mmHg (1 mmHg = 0.133 kPa). According to the study of Guérin et al. [30] in patients with severe ARDS, early application of prolonged prone-positioning sessions for at least 16 h significantly decreased 28-day and 90-day mortality. With respect to the duration of the prone position, it has been strongly recommended that adult patients with severe ARDS receive prone positioning for more than 12 h/day. [31] Although the optimal approach to PEEP titration has not yet been established, oxygenation-based PEEP titration is the most commonly used method related to lung recruitability. The ARDSNet FiO 2 -PEEP table is one of the simple oxygenation-based methods for initial PEEP setting. Furthermore, the oxygenation response should be considered during PEEP titration. Goligher et al. [32] found that patients with a positive oxygenation response (>25 mmHg increase in PaO 2 /FiO 2 ) of higher PEEP had lower mortality than those without a positive oxygenation response (crude mortality rate: 31.0% vs. 54.0%, adjusted odds ratio [OR]: 0.36, 95% CI: 0.23-0.58). These results indicated that higher PEEP will benefit patients with a positive oxygenation response of PEEP. Since lung recruitability is associated with the severity of ARDS, setting PEEP according to ARDS severity might be a simple but physiologically sound method. Gattinoni et al. [33] suggested that PEEP ranges of 5-10, 10-15, and >15 cmH 2 O should be used in mild, moderate, and severe ARDS, respectively. Individualized PEEP titrated by EIT, compliance, and transpulmonary pressure are helpful in selected ARDS patients.
acutE cor PulmonalE should not BE IgnorEd
Acute cor pulmonale (ACP) is common in severe ARDS patients and is always ignored. [34] The prevalence rate of echocardiographically evident ACP in ARDS ranges from 22.0% to 50.0%. [35] Treatment of ACP in ARDS includes optimization of right ventricle preload and afterload; increased right ventricle contractility, pulmonary vasodilators, and lung protective ventilation are the important methods for reducing right ventricle afterload. For severe ACP, RMs, prone ventilation, and extracorporeal life support can reverse the physiological causes of ACP and facilitate "RV-protective" ventilation; however, ARDS mortality has not been verified in clinical studies.
undErstandIng of molEcular mEchanIsm for acutE rEsPIratory dIstrEss syndromE Novel analytical techniques have been conducted for some of these accepted markers to refine ARDS endotypes or to serve as enrichment markers in future trials. Genome-wide association studies, next-generation sequencing, gene expression profiling, proteomics and metabolomics, and microbiome analysis have been used to select genetic variation and changes of expression of proteins and metabolites. Improved molecular understanding of the pathogenic contributors to ARDS could lead to individualized therapy for the inhomogeneous syndrome and could improve outcomes in the future.
ARDS has been a devastating clinical syndrome during the past 50 years, and its incidence and mortality remain high. The definition and treatment of ARDS are still confronted with challenges, and early recognition and intervention is crucial for improving the outcomes of ARDS. Precise lung protective strategy and early use of ECMO could improve the mortality rate of severe ARDS. More clinical studies are needed to improve early diagnosis and appropriate therapy. 
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